Drug Database
TA

tamsulosin (tamsulosin WOWTAB / Harnal D)

✓ Approved

Astellas Pharma · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namestamsulosin WOWTAB, Harnal D
CompanyAstellas Pharma
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedEuropean journal of translational myology2026-10-15

Cricoid pressure in contemporary airway management: a structured narrative review and call for competency-based implementation.

Stoyanova Zlatina Z, Trendafilova Petya P, Bozov Hristo H, Sandeva Milena M et al.

Cricoid Pressure (CP) remains one of the most debated interventions during rapid sequence induction. Although traditionally used to reduce Pulmonary Aspiration (PA), its effectiveness remains uncertain because of conflicting clinical evidence and considerable variability in its application. This structured narrative review critically evaluates contemporary evidence regarding the anatomical rationale, clinical effectiveness, safety, guideline recommendations, performance errors, simulation-based training, and competency-based education for CP. A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science through July 2026, including randomized controlled trials, systematic reviews, meta-analyses, anatomical studies, clinical guidelines, and educational research. Current evidence does not conclusively demonstrate that CP reduces pulmonary aspiration, while inappropriate anatomical localization, excessive or insufficient force, incorrect timing, and delayed release may adversely affect airway management. Contemporary guidelines increasingly recommend selective rather than routine use of CP and emphasize prompt release whenever ventilation or tracheal intubation is compromised. Educational evidence consistently demonstrates that simulation incorporating objective force-feedback improves immediate technical performance; however, evidence for long-term skill retention, clinical transfer, and patient-centered outcomes remains limited. A six-stage competency-based simulation training curriculum is proposed to standardize training, objective assessment, and periodic reassessment of CP performance. The review also discusses opportunities for implementing CPE within Bulgarian medical training.

PubMedCureus2026-10-15

Correction: Immediate and Intermediate-Term Outcomes of Right Ventricular Outflow Tract Interventions in Neonates and Infants: A Prospective Single-Center Study.

Champaneri Bhavik B, Garhwal Vicky V, Pota Abhay A, Parmar Tarun T et al.

[This corrects the article DOI: 10.7759/cureus.92516.].

PubMedNature communications2026-10-15

On-demand design of controlled-release systems using an expert-mimic AI framework.

Qin Ying Y, Zhou Rushuang R, Ming Yali Y, Li Bohao B et al.

Navigating a vast formulation-preparation design space that is highly sensitive to perturbations makes trial-and-error approaches inefficient and costly for diverse clinical needs. Here, we introduce an expert-mimic AI framework called E-MAF that integrates a process-aware surrogate with an optimized genetic algorithm to emulate coarse-to-fine reasoning, autonomously generating lab-ready designs tailored to desired release profiles. We show that E-MAF delivers on-demand release and shortens design cycles from 6-12 months to approximately 1 hour. We demonstrate that in vitro release, in vivo pharmacokinetics and therapeutic effects match or surpass commercial benchmarks across 7 active pharmaceutical ingredients. We show that E-MAF also enables release profiles that are hard to achieve by conventional approaches, exemplified by ≤2% risperidone burst within 1 h and near-zero-order release over ~28 days in vivo. These results demonstrate E-MAF's potential to accelerate polymeric controlled-release system development and drug-delivery industrialization.

PubMedFrontiers in psychology2026-10-15

Responsible use of generative AI in Chinese vocational education: eye-tracking evidence on source verification and immediate near-transfer across three information-seeking conditions.

Ma Ji J, Yue Hongjie H, Li Xinyang X

Generative artificial intelligence (GenAI) can streamline information screening and integration in vocational learning, but easy access to fluent answers may reduce students' tendency to check sources. Drawing on a dual-process perspective, this study compared GenAI-only, conventional web-search, and hybrid-search conditions in terms of source verification, task trust, perceived cognitive load, and condition-supported immediate near-transfer performance. Ninety-six vocational college students took part in a three-group, between-subjects eye-tracking experiment. After stratification by year of study, disciplinary cluster, and prior AI-use experience, they were randomly assigned to the three conditions (n = 32 each). Eye-tracking data, screen-recorded behavioral logs, questionnaires, and task scores were examined using between-group comparisons, correlation analyses, and hierarchical regression. GenAI-only participants completed the two timed tasks fastest and reported the lowest perceived cognitive load and the highest task trust, but they devoted less attention to source evidence, made fewer cross-verification attempts, and revised their answers less often. Conventional web search involved more multi-source browsing and evidence comparison but required the most time. Hybrid search showed the highest source-evidence dwell proportion (27.9%), cross-verification-attempt rate (78.1%), and immediate near-transfer score (86.99), and outperformed both other conditions on near-transfer performance. After adjustment for search condition and prior tool experience, source-evidence dwell proportion (β = 0.28, p = 0.006) and cross-verification attempts (β = 0.31, p = 0.002) remained positively associated with near-transfer performance, whereas task trust did not. The three search modes showed different trade-offs between efficiency, verification, and task performance. GenAI-only search reduced completion time and overall perceived cognitive load, whereas hybrid search was associated with more source checking and better immediate near-transfer performance under the assigned condition. These findings suggest that GenAI can support problem framing and information organization when learners continue to verify evidence and retain responsibility for final judgments.

PubMedCancer discovery2026-10-15

Binding-To-Release Enhances Efficacy of Small Molecule-Drug Conjugates.

PubMedFrontiers in pain research (Lausanne, Switzerland)2026-10-15

Comparative evaluation of the antipyretic and analgesic efficacy and safety of a fast-release paracetamol 650 mg formulation vs. conventional paracetamol formulations in adults with acute febrile or febrile-pain conditions: a multicenter randomized controlled trial.

Mondal Susobhan S, Ikbal S K Ashik SKA, Agrawal Sumit S, Raykantiwar Amar A et al.

Paracetamol is widely used for management of fever/pain. With increasing emphasis on rapid symptom relief, this study compared the response following a single 650 mg oral dose of four commercially available tablets in acute febrile and febrile-pain conditions. This multicenter, open-label trial (CTRI/2025/12/098995) included adults (18-60 years) with oral temperature ≥38 °C (with/without pain) and symptom onset within ≤72 h. Consenting participants were randomized (1:1:1:1) to receive a single dose of the test fast release test paracetamol (A) and conventional paracetamol (B, C, D) drug. Oral body temperature(digital thermometer) and pain (numerical rating scale (NRS) were assessed at predefined intervals till 90 ± 2 min. Outcomes included magnitude and onset of antipyretic and analgesic effects, adverse events (AEs), and patient satisfaction. Among 220 febrile participants (55% women; mean temperature 38.51 °C), 169 reported pain (mean NRS score 7.31). At 90 ± 2 min, fast release paracetamol demonstrated significantly greater reduction in temperature (1.54 °C), along with the fastest rate of decline (1.03 °C/hr), and the shortest restricted mean time to defervescence (84.27 min), resulting in majority of participants (60.0%) experiencing defervescence (temperature ≤37 °C). Pain reduction was also significantly greater with fast release test paracetamol (5.2 units; 3.4 units/hr), with onset of analgesia (≥30% reduction in NRS score) after a comparatively shorter median time (30 min; conventional, 60-90 min). By 90 ± 2 min, pain resolved (NRS score = 0) in 23.2% (A), 22.5% (B), 11.9% (C), and 6.8% (D) participants, with restricted mean times to resolution being 90.00, 89.25, 89.29, and 90.00 min, respectively. Overall, 82.2% participants reported treatment satisfaction, with likelihood highest for fast-release test paracetamol (A). Four participants reported unrelated, mild/moderate AEs. All evaluated paracetamol 650 mg formulations demonstrated antipyretic and analgesic activity within 90 min, while the fast-release formulation showed earlier and, for several assessed outcomes, greater reductions in temperature and pain. These findings may support consideration of formulation choice when rapid early symptomatic relief is desired. CTRI/2025/12/098995.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin